Rafael Bejar, MD, PhD, Director of the MDS Center of Excellence at the Moores Cancer Center of the University of San Diego, explains how testing for
genetic mutations and
chromosomal abnormalities can help your doctor
personalize your
MDS therapy. For example, risk-based therapy based on a
5q deletion can lead to therapy with lenalidomide and mutations on the
IDH genes can lead to treatment with specific chemotherapy drugs.
-
Share with family and friends:
Click here to take our SURVEY
Your feedback is important to us! We will use your feedback to develop future areas of content about MDS which will help other patients, caregivers and families.